Cancer pharmacogenomics and pharmacoepidemiology

Setting a research agenda to accelerate translation

Andrew N. Freedman, Leah B. Sansbury, William D. Figg, Arnold L. Potosky, Sheila R. Weiss Smith, Muin J. Khoury, Stefanie A. Nelson, Richard M Weinshilboum, Mark J. Ratain, Howard L. McLeod, Robert S. Epstein, Geoffrey S. Ginsburg, Richard L. Schilsky, Geoffrey Liu, David A. Flockhart, Cornelia M. Ulrich, Robert L. Davis, Lawrence J. Lesko, Issam Zineh, Gurvaneet Randhawa & 8 others Christine B. Ambrosone, Mary V. Relling, Nat Rothman, Heng Xie, Margaret R. Spitz, Rachel Ballard-Barbash, James H. Doroshow, Lori M. Minasian

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled "Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation" on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructure-based recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen- and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice.

Original languageEnglish (US)
Pages (from-to)1698-1705
Number of pages8
JournalJournal of the National Cancer Institute
Volume102
Issue number22
DOIs
StatePublished - Nov 2010

Fingerprint

Pharmacoepidemiology
Pharmacogenetics
National Cancer Institute (U.S.)
Research
Neoplasms
Clinical Trials
Education
Second Primary Neoplasms
Information Dissemination
Life Style
Industry
Research Personnel
Drug Therapy
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Freedman, A. N., Sansbury, L. B., Figg, W. D., Potosky, A. L., Weiss Smith, S. R., Khoury, M. J., ... Minasian, L. M. (2010). Cancer pharmacogenomics and pharmacoepidemiology: Setting a research agenda to accelerate translation. Journal of the National Cancer Institute, 102(22), 1698-1705. https://doi.org/10.1093/jnci/djq390

Cancer pharmacogenomics and pharmacoepidemiology : Setting a research agenda to accelerate translation. / Freedman, Andrew N.; Sansbury, Leah B.; Figg, William D.; Potosky, Arnold L.; Weiss Smith, Sheila R.; Khoury, Muin J.; Nelson, Stefanie A.; Weinshilboum, Richard M; Ratain, Mark J.; McLeod, Howard L.; Epstein, Robert S.; Ginsburg, Geoffrey S.; Schilsky, Richard L.; Liu, Geoffrey; Flockhart, David A.; Ulrich, Cornelia M.; Davis, Robert L.; Lesko, Lawrence J.; Zineh, Issam; Randhawa, Gurvaneet; Ambrosone, Christine B.; Relling, Mary V.; Rothman, Nat; Xie, Heng; Spitz, Margaret R.; Ballard-Barbash, Rachel; Doroshow, James H.; Minasian, Lori M.

In: Journal of the National Cancer Institute, Vol. 102, No. 22, 11.2010, p. 1698-1705.

Research output: Contribution to journalArticle

Freedman, AN, Sansbury, LB, Figg, WD, Potosky, AL, Weiss Smith, SR, Khoury, MJ, Nelson, SA, Weinshilboum, RM, Ratain, MJ, McLeod, HL, Epstein, RS, Ginsburg, GS, Schilsky, RL, Liu, G, Flockhart, DA, Ulrich, CM, Davis, RL, Lesko, LJ, Zineh, I, Randhawa, G, Ambrosone, CB, Relling, MV, Rothman, N, Xie, H, Spitz, MR, Ballard-Barbash, R, Doroshow, JH & Minasian, LM 2010, 'Cancer pharmacogenomics and pharmacoepidemiology: Setting a research agenda to accelerate translation', Journal of the National Cancer Institute, vol. 102, no. 22, pp. 1698-1705. https://doi.org/10.1093/jnci/djq390
Freedman, Andrew N. ; Sansbury, Leah B. ; Figg, William D. ; Potosky, Arnold L. ; Weiss Smith, Sheila R. ; Khoury, Muin J. ; Nelson, Stefanie A. ; Weinshilboum, Richard M ; Ratain, Mark J. ; McLeod, Howard L. ; Epstein, Robert S. ; Ginsburg, Geoffrey S. ; Schilsky, Richard L. ; Liu, Geoffrey ; Flockhart, David A. ; Ulrich, Cornelia M. ; Davis, Robert L. ; Lesko, Lawrence J. ; Zineh, Issam ; Randhawa, Gurvaneet ; Ambrosone, Christine B. ; Relling, Mary V. ; Rothman, Nat ; Xie, Heng ; Spitz, Margaret R. ; Ballard-Barbash, Rachel ; Doroshow, James H. ; Minasian, Lori M. / Cancer pharmacogenomics and pharmacoepidemiology : Setting a research agenda to accelerate translation. In: Journal of the National Cancer Institute. 2010 ; Vol. 102, No. 22. pp. 1698-1705.
@article{e35f12b7205b440aa5e3e5b34e52014b,
title = "Cancer pharmacogenomics and pharmacoepidemiology: Setting a research agenda to accelerate translation",
abstract = "Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled {"}Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation{"} on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructure-based recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen- and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice.",
author = "Freedman, {Andrew N.} and Sansbury, {Leah B.} and Figg, {William D.} and Potosky, {Arnold L.} and {Weiss Smith}, {Sheila R.} and Khoury, {Muin J.} and Nelson, {Stefanie A.} and Weinshilboum, {Richard M} and Ratain, {Mark J.} and McLeod, {Howard L.} and Epstein, {Robert S.} and Ginsburg, {Geoffrey S.} and Schilsky, {Richard L.} and Geoffrey Liu and Flockhart, {David A.} and Ulrich, {Cornelia M.} and Davis, {Robert L.} and Lesko, {Lawrence J.} and Issam Zineh and Gurvaneet Randhawa and Ambrosone, {Christine B.} and Relling, {Mary V.} and Nat Rothman and Heng Xie and Spitz, {Margaret R.} and Rachel Ballard-Barbash and Doroshow, {James H.} and Minasian, {Lori M.}",
year = "2010",
month = "11",
doi = "10.1093/jnci/djq390",
language = "English (US)",
volume = "102",
pages = "1698--1705",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "22",

}

TY - JOUR

T1 - Cancer pharmacogenomics and pharmacoepidemiology

T2 - Setting a research agenda to accelerate translation

AU - Freedman, Andrew N.

AU - Sansbury, Leah B.

AU - Figg, William D.

AU - Potosky, Arnold L.

AU - Weiss Smith, Sheila R.

AU - Khoury, Muin J.

AU - Nelson, Stefanie A.

AU - Weinshilboum, Richard M

AU - Ratain, Mark J.

AU - McLeod, Howard L.

AU - Epstein, Robert S.

AU - Ginsburg, Geoffrey S.

AU - Schilsky, Richard L.

AU - Liu, Geoffrey

AU - Flockhart, David A.

AU - Ulrich, Cornelia M.

AU - Davis, Robert L.

AU - Lesko, Lawrence J.

AU - Zineh, Issam

AU - Randhawa, Gurvaneet

AU - Ambrosone, Christine B.

AU - Relling, Mary V.

AU - Rothman, Nat

AU - Xie, Heng

AU - Spitz, Margaret R.

AU - Ballard-Barbash, Rachel

AU - Doroshow, James H.

AU - Minasian, Lori M.

PY - 2010/11

Y1 - 2010/11

N2 - Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled "Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation" on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructure-based recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen- and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice.

AB - Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled "Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation" on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructure-based recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen- and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=78649371176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649371176&partnerID=8YFLogxK

U2 - 10.1093/jnci/djq390

DO - 10.1093/jnci/djq390

M3 - Article

VL - 102

SP - 1698

EP - 1705

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 22

ER -